Evaluating the safety and efficacy of a Unani formulation in Psoriasis
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: L409- Psoriasis, unspecified
- Registration Number
- CTRI/2023/10/058549
- Lead Sponsor
- ational Research Institute of Unani Medicine for Skin Disorders
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1Patients of any sex aged between 18-60 years of age
2Patients clinically diagnosed with Taqashshur al-Jild (Psoriasis)
3Psoriasis area severity index (PASI) =10%
Exclusion Criteria
1Patients aged < 18 years or >60 years
2Known cases of Diabetes
3Pregnant or Lactating Women
4Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction
5Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies
6Patient not willing to attend treatment schedule regularly
7Patients with Psoriatic arthritis
8Erythrodermic psoriasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in mean PASI from baselineTimepoint: 84 DAYS
- Secondary Outcome Measures
Name Time Method Improvement in DLQI from baselineTimepoint: 84 Days;Improvement in IGA from baselineTimepoint: 84 Days